Drugs News and Research

RSS

iRGD peptide found to enhance both cancer detection and treatment

Researchers at Burnham Institute for Medical Research at University of California, Santa Barbara have identified a peptide (a chain of amino acids) that specifically recognizes and penetrates cancerous tumors but not normal tissues.

8 Dec 2009

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers reported today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Caffeinated energy drink does not neutralize alcohol intoxication, says new study

People who drink may want to know that coffee won't sober them up, according to new laboratory research. Instead, a cup of coffee may make it harder for people to realize they're drunk.

8 Dec 2009

Investigation: Temp firms often employ incompetent nurses

"Firms that supply temporary nurses to the nation's hospitals are taking perilous shortcuts in their screening and supervision, sometimes putting seriously ill patients in the hands of incompetent or impaired caregivers," ProPublica and The Los Angeles Times report. "Emboldened by a chronic nursing shortage and scant regulation, the firms vie for their share of a free-wheeling, $4-billion industry. Some have become havens for nurses who hopscotch from place to place to avoid the consequences of their misconduct."

7 Dec 2009

Cysteine-rich whey protein supplement may maintain or increase weight in advanced NSCLC patients

Immunotec Inc. announced today the enrollment of the first patient in the US Cancer trial of IMN 1207 being run at Beaumont Hospital's Community Clinical Oncology Program (CCOP) in Royal Oak, Michigan. The goal of the study is to determine the effect of IMN 1207, a cysteine-rich whey protein supplement, in preventing additional weight loss in patients with stage IV (advanced) non-small cell lung cancer.

7 Dec 2009

Deals on health reform in jeopardy as support from drugmakers, senior groups is tested

The pharmaceutical industry's support for a health care reform bill in the Senate is in jeopardy as Senate Democrats ponder squeezing more cost savings out of drug makers to help pay for the overhaul, The Associated Press reports.

7 Dec 2009

Some progress on health bill, Senators prepare for long December

"Senate Republicans and Democrats are digging in for a long December, vowing they have no objection to the possibility of a working Christmas to debate healthcare reform," The Hill reports. "From GOP rank-and-file to Democratic leaders, senators say they regret but recognize the need to put public duty ahead of their families and follow a schedule tentatively laid out by Majority Leader Harry Reid (D-Nev.). Reid has said he may call the chamber back into session in between the Christmas and New Year's holidays" (Rushing, 12/6).

7 Dec 2009

$225,000 funding for promising epilepsy research

The Epilepsy Research Foundation (ERF), a unique joint venture of non-profit epilepsy organizations, and the Milken Family Foundation, a private philanthropic foundation, today announced two new grants recognizing promising epilepsy research in clinical development, totaling $225,000 in funding. The grant awards were announced by the Epilepsy Therapy Project and the Epilepsy Foundation, as well as the Milken Family Foundation, during the 7th Judith Hoyer Lecture in Epilepsy at the annual meeting of the American Epilepsy Society in Boston, MA.

7 Dec 2009

Synta Pharmaceuticals announces study results of elesclomol

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the results of a study evaluating the activity of elesclomol against acute myeloid leukemia (AML) cell lines and primary leukemic blast cells from AML patients, presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

7 Dec 2009

Native Remedies selects TransMedia Group as its PR firm

With more than 500,000 customers worldwide, the market leader in all-natural herbal and homeopathic remedies for people and their pets, Native Remedies, has engaged TransMedia Group as their PR firm of record. The company's two brands, Native Remedies (www.nativeremedies.com) and PetAlive (www.PetAlive.com), provide complete lines of safe, scientifically-tested, guaranteed products that promote health and wellness - naturally.

7 Dec 2009

ICON, CMFT collaborate to develop translational medicine facilities on the MRI campus

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced details of its new translational medicine unit in Manchester, UK. The unit is the first deliverable from a collaborative agreement between ICON and the Central Manchester University Hospitals Foundation (CMFT) to develop purpose-built translational medicine facilities on the newly-developed Manchester Royal Infirmary (MRI) campus.

7 Dec 2009

Micromedex 2.0, the new version of clinical information system to be released

Thomson Reuters today announced the release of Micromedex 2.0, the newest version of its market-leading clinical information system.

7 Dec 2009

New oral drug is safe and effective to combat clotting disorder

A new study provides welcome news for patients with a common clotting disorder known as venous thromboembolism (VTE).

7 Dec 2009

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Gloucester Pharmaceuticals announced today the presentation of positive data from an analysis of ISTODAX® (romidepsin) in a subset of patients from Gloucester’s registration study in cutaneous T-cell lymphoma (CTCL) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

7 Dec 2009

Computer search algorithms identify FDA-approved drugs that could be the basis for new medicines

A massive, data-crunching computer search program that matches fragments of potential drug molecules to the known shapes of viral surface proteins has identified several FDA-approved drugs that could be the basis for new medicines -- if emerging viruses such as the H5N1(avian flu) or H1N1/09 (swine flu) develop resistance to current antiviral therapies -- according to a presentation at the American Society for Cell Biology (ASCB) 49th Annual Meeting, Dec. 5-9, 2009 in San Diego.

7 Dec 2009

Positive clinical data from Phase II study of elacytarabine in patients with AML reported

Clavis Pharma ASA announces that positive clinical data from its Phase II study with its lead cancer product candidate elacytarabine in patients with late-stage acute myeloid leukaemia (AML) was presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, LA, USA.

7 Dec 2009

SU2C awards $9.68 million to support high-risk cancer research

Stand Up To Cancer (SU2C) announced today that it is awarding $9.68 million to support high-risk/high-reward cancer research conducted by 13 young scientists.

7 Dec 2009

Anticoagulants used to prevent clots in placental blood vessels ineffective, reveals research

Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. Sometimes, however, clots form on the inside of vessels without an obvious injury or do not dissolve naturally, a potentially life-threatening situation requiring treatment.

7 Dec 2009

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Gloucester Pharmaceuticals announced today the presentation of preclinical data demonstrating that the combination of ISTODAX® (romidepsin) and Velcade® (bortezomib) resulted in synergistic anti-tumor activity in B-cell non-Hodgkin's lymphoma cell lines.

7 Dec 2009

New three-drug combination may be effective for treating patients with bone cancer

A new three-drug combination has shown in a phase 1/2 clinical trial that it is a "highly effective regimen" in the treatment of patients newly diagnosed with multiple myeloma, a cancer of white blood cells in bone marrow, say researchers from Dana-Farber Cancer Institute.

7 Dec 2009

Drugs News and Research

iRGD peptide found to enhance both cancer detection and treatment

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

Caffeinated energy drink does not neutralize alcohol intoxication, says new study

Investigation: Temp firms often employ incompetent nurses

Cysteine-rich whey protein supplement may maintain or increase weight in advanced NSCLC patients

Deals on health reform in jeopardy as support from drugmakers, senior groups is tested

Some progress on health bill, Senators prepare for long December

$225,000 funding for promising epilepsy research

Synta Pharmaceuticals announces study results of elesclomol

Native Remedies selects TransMedia Group as its PR firm

ICON, CMFT collaborate to develop translational medicine facilities on the MRI campus

Micromedex 2.0, the new version of clinical information system to be released

New oral drug is safe and effective to combat clotting disorder

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Computer search algorithms identify FDA-approved drugs that could be the basis for new medicines

Positive clinical data from Phase II study of elacytarabine in patients with AML reported

SU2C awards $9.68 million to support high-risk cancer research

Anticoagulants used to prevent clots in placental blood vessels ineffective, reveals research

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

New three-drug combination may be effective for treating patients with bone cancer

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News